AmacaThera is commercialising a novel biomaterial developed by the Shoichet Laboratory at University of Toronto. Molly Shoichet’s laboratory has developed HAMC, a platform technology that can be used to increase the length of time a drug is effective. HAMC is a reversible and fast gelling physical blend of hyaluronan (HA) and methyl cellulose (MC) that liquefies under shear force and re-gels immediately on extrusion – HAMC can be injected from a syringe into small spaces and gels at body temperature. Using pain medication formulated in HAMC we are investigating the reduction of pain after both general surgery and back surgery.
AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications.